A phase I trial of the HSP90 inhibitor, alvespimycin (17-DMAG) administered weekly, intravenously, to patients with advanced, solid tumours.

@article{Pacey2009API,
  title={A phase I trial of the HSP90 inhibitor, alvespimycin (17-DMAG) administered weekly, intravenously, to patients with advanced, solid tumours.},
  author={Simon Pacey and Richard J. Wilson and Michael I. Walton and Martin M. Eatock and Anna Zetterlund and Hendrik-Tobias Arkenau and Rowena Beecham and F I Raynaud and Paul Workman and Ian Judson},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2009},
  volume={27 15_suppl},
  pages={3534}
}
3534 Background: alvespimycin (17-dimethylaminoethylamino-17-demethoxygeldanamycin, 17-DMAG) inhibits N-terminal ATPase activity of Heat Shock Protein 90 (HSP90). Chaperone interactions are altered such that client proteins are targeted for degradation. The plethora of HSP90 client proteins offers the potential of simultaneous blockade across multiple, oncogenic signalling pathways. METHODS the maximum tolerated dose, at which ≤ 1/6 patients experienced dose limiting toxicity (DLT) was… CONTINUE READING